Evaluation of the Clinic Efficacy of Immunoglobulin Anti-RhD KamRho-D® (Panamerican) in Postpartum Immunization of Rh-negative and Coombs Negative Women at Sensitization Risk.

Trial Profile

Evaluation of the Clinic Efficacy of Immunoglobulin Anti-RhD KamRho-D® (Panamerican) in Postpartum Immunization of Rh-negative and Coombs Negative Women at Sensitization Risk.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2016

At a glance

  • Drugs Anti-D Rh0 immunoglobulin (Primary) ; Immune globulin
  • Indications Haemolytic disease of newborn
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Apr 2016 Treatment arms changed from 2 to 1(comparator drug Rhophylac removed), study design changed from parallel, randomised to single group assignment as reported by ClinicalTrials.gov.
    • 07 Apr 2016 Planned End Date changed from 1 Feb 2015 to 1 Nov 2017 as reported by ClinicalTrials.gov.
    • 07 Apr 2016 Planned primary completion date changed from 1 Feb 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top